After a period of cautious investor sentiment that chilled the life sciences sector, Aktis Oncology is making a decisive move into the public domain with an initial public offering that could signal a significant turning point for the industry. The company, a specialist in targeted
In the rapidly evolving pharmaceutical landscape, a fundamental strategic shift is underway as the very definition of a valuable brand is being rewritten. While individual product brands like Ozempic and Mounjaro have achieved unprecedented celebrity status and captured the public imagination,
The journey from a promising biological target to a life-saving therapeutic is fraught with challenges, where the quality and reliability of experimental data can mean the difference between a breakthrough and a dead end. For years, the scientific community has relied on established methods to
The intricate web of biochemical reactions occurring within our cells every second represents a foundational, yet often overlooked, frontier in medical science. Metabolism assays, the analytical tools designed to measure these vital processes, are emerging as a linchpin in the future of healthcare,
The future of medicine is no longer being synthesized exclusively in a chemistry lab; it is being grown, cultivated, and programmed within the very biological systems it is designed to heal. A transformative class of treatments known as biologics is fundamentally altering the therapeutic landscape,
In the intricate landscape of South Korean corporate governance, a critical legislative proposal aimed at empowering shareholders has inadvertently triggered a wave of defensive maneuvers by some of the nation's leading pharmaceutical companies. As lawmakers debate a reform that would force
